Cite
HARVARD Citation
Locatelli, F. et al. (2018). Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet. 5 (10), pp. e450-e461. [Online].